MoonLake completes randomization of patients for Phase 2 trial

MoonLake Immunotherapeutics announced that it has successfully completed randomization of the target 200 patients, several weeks ahead of schedule, in its global Phase 2 ARGO clinical trial evaluating Nanobody sonelokimab in active psoriatic arthritis. MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023. Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “ARGO is MoonLake’s second trial to have achieved faster completion of recruitment and randomization than expected. Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs. We are looking forward to all of the upcoming key MoonLake readouts and events and are excited about updating investors with our progress in due course.”